Antibody evasion associated with the RBD significant mutations in several emerging SARS-CoV-2 variants and its subvariants

被引:5
|
作者
Bhattacharya, Manojit [1 ]
Chatterjee, Srijan [2 ]
Lee, Sang-Soo [2 ]
Dhama, Kuldeep [3 ]
Chakraborty, Chiranjib [4 ]
机构
[1] Fakir Mohan Univ, Dept Zool, Balasore 756020, Odisha, India
[2] Hallym Univ, Chuncheon Sacred Heart Hosp, Inst Skeletal Aging & Orthopaed Surg, Chuncheon Si 24252, Gangwon Do, South Korea
[3] ICAR Indian Vet Res Inst, Div Pathol, Bareilly 243122, Uttar Pradesh, India
[4] Adamas Univ, Sch Life Sci & Biotechnol, Dept Biotechnol, Kolkata 700126, W Bengal, India
关键词
RBD mutations; Vaccine escape; Immune escape; Variants of SARS-CoV-2; RECEPTOR-BINDING DOMAIN; SPIKE PROTEIN; OMICRON; ESCAPE; REGION; CHINA;
D O I
10.1016/j.drup.2023.101008
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Since the origin of the wild strain of SARS-CoV-2, several variants have emerged, which were designated as VOC, VOI, and VUM from time to time. The Omicron variant is noted as the recent VOC. After the origin of the Omicron variant on November 2021, several subvariants of Omicron have originated subsequently, like BA.1/2, BA.2.75/2.75.2, BA.4/5, BF.7, BQ.1/1.1, XBB.1/1.5, etc. which are circulated throughout the globe. Scientists reported that antibody escape is a common phenomenon observed in all the previous VOCs, VOIs, including Omicron and its subvariants. The mutations in the NTD (N-terminal domain) and RBD (Receptor-binding domain) of the spike of these variants and subvariants are responsible for antibody escape. At the same time, it has been noted that spike RBD mutations have been increasing in the last few months. This review illustrates significant RBD mutations namely R346T, K417N/T, L452R, N460K E484A/K/Q, and N501Y found in the previous emerging SARS-CoV-2 variants, including Omicron and its subvariants in high frequency and their role in antibody evasion and immune evasion. The review also describes the different classes of nAb responsible for antibody escape in SARS-CoV-2 variants and the molecular perspective of the mutation in nAb escape. It will help the future researchers to develop efficient vaccines which can finally prevent the pandemic.
引用
收藏
页数:17
相关论文
共 50 条
  • [31] Molecular strategies for antibody binding and escape of SARS-CoV-2 and its mutations
    Hendy, Mohamed
    Kaufman, Samuel
    Ponga, Mauricio
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [32] An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants
    Chi, Xiaojing
    Zhang, Xinhui
    Pan, Shengnan
    Yu, Yanying
    Shi, Yujin
    Lin, Tianli
    Duan, Huarui
    Liu, Xiuying
    Chen, Wenfang
    Yang, Xuehua
    Chen, Lan
    Dong, Xiaoqian
    Ren, Lili
    Ding, Qiang
    Wang, Jianwei
    Yang, Wei
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2022, 7 (01)
  • [33] Impact of SARS-CoV-2 RBD Mutations on the Production of a Recombinant RBD Fusion Protein in Mammalian Cells
    Gerez, Guillaume
    Martinez, Jerome
    Steinbrugger, Christophe
    Bouanich, Sandra
    Dimino, Johanna
    Piegay, Corine
    Combe, Maxime
    Berthier, Franck
    Daniel, Soizic
    BIOMOLECULES, 2022, 12 (09)
  • [34] Somatic hypermutation introduces bystander mutations that prepare SARS-CoV-2 antibodies for emerging variants
    Korenkov, Michael
    Zehner, Matthias
    Cohen-Dvashi, Hadas
    Borenstein-Katz, Aliza
    Kottege, Lisa
    Janicki, Hanna
    Vanshylla, Kanika
    Weber, Timm
    Gruell, Henning
    Koch, Manuel
    Diskin, Ron
    Kreer, Christoph
    Klein, Florian
    IMMUNITY, 2023, 56 (12) : 2803 - 2815.e6
  • [35] A protein vaccine of RBD integrated with immune evasion mutation shows broad protection against SARS-CoV-2
    An, Ran
    Yang, Hao
    Tang, Cong
    Li, Qianqian
    Huang, Qing
    Wang, Haixuan
    Wang, Junbin
    Zhou, Yanan
    Yang, Yun
    Chen, Hongyu
    Yu, Wenhai
    Li, Bai
    Wu, Daoju
    Zhang, Yong
    Luo, Fangyu
    Quan, Wenqi
    Xu, Jingwen
    Lin, Dongdong
    Liang, Xiaoming
    Yan, Yuhuan
    Yuan, Longhai
    Du, Xuena
    Yuan, Yuxia
    Li, Yanwen
    Sun, Qiangming
    Wang, Youchun
    Lu, Shuaiyao
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)
  • [36] Anti-Spike Antibody Response to Natural Infection with SARS-CoV-2 and Its Activity against Emerging Variants
    Chen, Cheng-Pin
    Huang, Kuan-Ying A.
    Shih, Shin-Ru
    Lin, Yi-Chun
    Cheng, Chien-Yu
    Huang, Yhu-Chering
    Lin, Tzou-Yien
    Cheng, Shu-Hsing
    MICROBIOLOGY SPECTRUM, 2022, 10 (04):
  • [37] SARS-CoV-2 serotyping based on spike antigenicity and its implications for host immune evasion
    Ruan, Wenjing
    Gao, Pengyue
    Qu, Xiao
    Jiang, Junlan
    Zhao, Zhennan
    Qiao, Shitong
    Zhang, He
    Yang, Ting
    Li, Dedong
    Du, Pei
    Lu, Xuancheng
    Wang, Qihui
    Zhao, Xin
    Gao, George Fu
    EBIOMEDICINE, 2025, 114
  • [38] An early warning system for emerging SARS-CoV-2 variants
    Subissi, Lorenzo
    von Gottberg, Anne
    Thukral, Lipi
    Worp, Nathalie
    Munnink, Bas B. Oude
    Rathore, Surabhi
    Abu-Raddad, Laith J.
    Aguilera, Ximena
    Alm, Erik
    Archer, Brett N.
    Cohen, Homa Attar
    Barakat, Amal
    Barclay, Wendy S.
    Bhiman, Jinal N.
    Caly, Leon
    Chand, Meera
    Chen, Mark
    Cullinane, Ann
    de Oliveira, Tulio
    Drosten, Christian
    Druce, Julian
    Effler, Paul
    El Masry, Ihab
    Faye, Adama
    Gaseitsiwe, Simani
    Ghedin, Elodie
    Grant, Rebecca
    Haagmans, Bart L.
    Herring, Belinda L.
    Iyer, Shilpa S.
    Kassamali, Zyleen
    Kakkar, Manish
    Kondor, Rebecca J.
    Leite, Juliana A.
    Leo, Yee-Sin
    Leung, Gabriel M.
    Marklewitz, Marco
    Moyo, Sikhulile
    Mendez-Rico, Jairo
    Melhem, Nada M.
    Munster, Vincent
    Nahapetyan, Karen
    Oh, Djin-Ye
    Pavlin, Boris, I
    Peacock, Thomas P.
    Peiris, Malik
    Peng, Zhibin
    Poon, Leo L. M.
    Rambaut, Andrew
    Sacks, Jilian
    NATURE MEDICINE, 2022, 28 (06) : 1110 - 1115
  • [39] Emerging Vaccine-Breakthrough SARS-CoV-2 Variants
    Wang, Rui
    Chen, Jiahui
    Hozumi, Yuta
    Yin, Changchuan
    Wei, Guo-Wei
    ACS INFECTIOUS DISEASES, 2022, 8 (03): : 546 - 556
  • [40] Potent neutralizing RBD-specific antibody cocktail against SARS-CoV-2 and its mutant
    Jia, Lina
    Liu, Yan-Ping
    Tian, Li-Fei
    Xiong, Chao
    Xu, Xin
    Qu, Honge
    Xiong, Weixi
    Zhou, Dong
    Wang, Feng
    Liu, Zheng
    Yan, Xiao-Xue
    Xu, Wenqing
    Tang, Lin
    MEDCOMM, 2021, 2 (03): : 442 - 452